about
Pharmaceutical policies: effects of financial incentives for prescribersPharmaceutical policies: effects of sales and dispensing policiesImproving access to medicines for non-communicable diseases in rural India: a mixed methods study protocol using quasi-experimental designAccess to essential medicines in Pakistan: policy and health systems research concernsEssential Medicines in a High Income Country: Essential to Whom?Overdependence on For-Profit Pharmacies: A Descriptive Survey of User Evaluation of Medicines Availability in Public Hospitals in Selected Nigerian StatesStakeholders' perspectives on access-to-medicines policy and research priorities in Latin America and the Caribbean: face-to-face and web-based interviews.Promoting transparency, accountability, and access through a multi-stakeholder initiative: lessons from the medicines transparency alliance.A cross-sectional pilot study assessing needs and attitudes to implementation of Information and Communication Technology for rational use of medicines among healthcare staff in rural Tanzania.Defining pharmaceutical systems strengthening: concepts to enable measurementThe need to look at antibiotic resistance from a health systems perspective.Access, excess, and ethics--towards a sustainable distribution model for antibioticsComparison of medicines management strategies in insurance schemes in middle-income countries: four case studiesIn which developing countries are patents on essential medicines being filed?Health system barriers to access and use of magnesium sulfate for women with severe pre-eclampsia and eclampsia in Pakistan: evidence for policy and practiceEssential Medicines in National Constitutions: Progress Since 2008.Consistent defined threshold and equity in health.Medicines and universal health coverage: challenges and opportunitiesHealth policy evolution in Lao People's Democratic Republic: context, processes and agencyThe reality of task shifting in medicines management- a case study from Tanzania.Evaluating the effect of a proposed logistics fee cap on pharmaceuticals in South Africa--a pre and post analysisAccess to Treatment for Diabetes and Hypertension in Rural Cambodia: Performance of Existing Social Health Protection Schemes.Barriers in household access to medicines for chronic conditions in three Latin American countries.Perceptions and utilization of generic medicines in Guatemala: a mixed-methods study with physicians and pharmacy staff.Inequalities in medicine use in Central Eastern Europe: an empirical investigation of socioeconomic determinants in eight countries.Affordability of medicines in the European UnionEvidence on access to medicines for chronic diseases from household surveys in five low- and middle-income countries.How social policies can improve financial accessibility of healthcare: a multi-level analysis of unmet medical need in European countries.Estimated Financing Amount Needed for Essential Medicines in China, 2014.Access to medicines in Latin America and the Caribbean (LAC): a scoping study.Using health markets to improve access to medicines: three case studies.Access to Medications for Cardiovascular Diseases in Low- and Middle-Income CountriesArticle 1: Supervision, Performance Assessment, and Recognition Strategy (SPARS) - a multipronged intervention strategy for strengthening medicines management in Uganda: method presentation and facility performance at baseline.Novel models to improve access to medicines for chronic diseases in South Africa: an analysis of stakeholder perspectives on community-based distribution modelsHealth policy and systems research in access to medicines: a prioritized agenda for low- and middle-income countriesAccess to medicines for chronic diseases in Brazil: a multidimensional approach.The imperative for systems thinking to promote access to medicines, efficient delivery, and cost-effectiveness when implementing health financing reforms: a qualitative study.Challenges in a product development partnership: a malaria treatment case study.ESMO European Consortium Study on the availability, out-of-pocket costs and accessibility of antineoplastic medicines in Europe.Analyzing implementation dynamics using theory-driven evaluation principles: lessons learnt from a South African centralized chronic dispensing model.
P2860
Q24188018-C9418FED-869E-42FA-B4B2-D8580DB8FE16Q24188073-489EB676-C2B4-4142-81D8-3FB56704F9EEQ27305295-609CF11E-49C3-4EC5-951B-4BC09CBB53C8Q28533249-9B9A8764-FE7D-4EDC-9A4F-D78B19679289Q28551437-3ACF992D-0BDC-4B62-9D91-B04856A3BB01Q28553191-A8D02EC3-E6D4-4495-9A40-3B6C37D1171EQ29353701-FE3C1B0A-4A96-4188-8F52-44E6AA9D6012Q30376595-66DA7E4E-997E-47E2-A6FA-B9A143804174Q30390767-BFB73D7D-0203-420D-982D-58AD8DC99298Q33589594-6485D0A9-715D-4985-91B6-45D263D23C68Q33667503-D7017905-303E-49F7-A125-BAD2E048E5F8Q33667517-F1FDFA85-411A-4794-8594-6448E1AD47EFQ33697280-23D7EE6E-3AE4-4966-9C09-DC6206B34BCCQ33837177-6C9459FE-66E2-45DF-BBC0-779792D4B57CQ34650803-E754B4F6-7254-49AD-A693-7B515FE188B1Q34679441-402CE712-88E1-4444-833C-14F5213E4626Q35101224-CDCFFDF5-BD19-4114-86D1-94A96AAF0D1DQ35149420-46E18B85-000B-4034-8A02-9B3A9DDF1E3DQ35273228-61CC4804-7740-4F76-B057-F8185D09E8BBQ35379883-A114E5CB-466D-4146-A6A7-3AEA85920EE0Q35854089-04594F70-3FD3-42CF-A66B-5F305CEBDA88Q35905686-35051B16-932B-4052-8705-A681E1D52BD5Q36234808-01E58D47-08C7-48FD-9D81-2C4ECDBB03C4Q36249454-3FA97E52-15E8-47A0-9DC9-925BAAB85722Q36255229-C57B50A6-D583-4DF3-B77C-2D1B35F34AB4Q36291455-2F4D4549-1790-48E3-B2C7-567F94F92A45Q36303856-191F4C05-BDD5-45BF-AE93-87F8B2B742F0Q36654311-1FA59550-3808-4EAD-9183-BFC239A16EE0Q36720011-EABF8721-5674-4227-B9F0-609A4BE88B09Q36821768-52C9C975-3C2B-4F5C-AC03-65CEF5BB627FQ36879731-6EFA874D-07E3-4548-A4D9-3FBF4F852C30Q36936076-0C7F36F4-ECC2-4C96-BF73-A7C30F1484BAQ36955498-05868609-1D8C-4DB6-B4F1-DE32F5D4137EQ37302462-80078647-029E-4A99-B11C-FF962CA6ADB2Q37370574-DC40A74B-2FDA-435D-85AE-BD44900AA951Q37505807-7959A231-9DFE-42CB-BDA3-6F17ABC78337Q37715839-BD527A5D-9890-441F-8C76-8441E6524CAFQ38655087-B4BBE75E-741D-4849-8655-64040B063E5DQ38908352-2530C7A0-318E-4228-AFE8-72D41378A2B4Q46342235-E955F164-FF13-4DA3-B401-3FCBEE183109
P2860
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Access to medicines from a health system perspective.
@en
Access to medicines from a health system perspective.
@nl
type
label
Access to medicines from a health system perspective.
@en
Access to medicines from a health system perspective.
@nl
prefLabel
Access to medicines from a health system perspective.
@en
Access to medicines from a health system perspective.
@nl
P2093
P2860
P356
P1476
Access to medicines from a health system perspective.
@en
P2093
Abdul Ghaffar
Bart Jacobs
Bruno Dujardin
Goran Tomson
Richard Laing
Wim Van Damme
P2860
P304
P356
10.1093/HEAPOL/CZS108
P577
2012-11-22T00:00:00Z
2013-10-01T00:00:00Z